Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms

P Zanos, R Moaddel, PJ Morris, LM Riggs… - Pharmacological …, 2018 - Elsevier
Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Detection and analysis of chiral molecules as disease biomarkers

Y Liu, Z Wu, DW Armstrong, H Wolosker… - Nature Reviews …, 2023 - nature.com
The chirality of small metabolic molecules is important in controlling physiological processes
and indicating the health status of humans. Abnormal enantiomeric ratios of chiral molecules …

Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers

D Matveychuk, RK Thomas… - Therapeutic …, 2020 - journals.sagepub.com
Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …

Efficacy and safety of perioperative application of ketamine on postoperative depression: a meta-analysis of randomized controlled studies

J Guo, D Qiu, H Gu, X Wang, K Hashimoto… - Molecular …, 2023 - nature.com
Ketamine, a commonly used general anesthetic, can produce rapid and sustained
antidepressant effect. However, the efficacy and safety of the perioperative application of …

A brief history of the development of antidepressant drugs: from monoamines to glutamate.

TM Hillhouse, JH Porter - Experimental and clinical …, 2015 - psycnet.apa.org
Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that
is the most common mood disorder in the United States. It has been almost 50 years since …

Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis

GC Medeiros, TD Gould, WL Prueitt, J Nanavati… - Molecular …, 2022 - nature.com
Abstract (R, S)-ketamine (ketamine) and its enantiomer (S)-ketamine (esketamine) can
produce rapid and substantial antidepressant effects. However, individual response to …

Mechanisms of action and persistent neuroplasticity by drugs of abuse

ER Korpi, B den Hollander, U Farooq… - Pharmacological …, 2015 - Elsevier
Adaptation of the nervous system to different chemical and physiologic conditions is
important for the homeostasis of brain processes and for learning and remembering …

Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review

ND Iadarola, MJ Niciu, EM Richards… - … advances in chronic …, 2015 - journals.sagepub.com
Current pharmacotherapies for major depressive disorder (MDD) and bipolar depression
(BDep) have a distinct lag of onset that can generate great distress and impairment in …

New targets for rapid antidepressant action

R Machado-Vieira, ID Henter, CA Zarate Jr - Progress in neurobiology, 2017 - Elsevier
Current therapeutic options for major depressive disorder (MDD) and bipolar disorder (BD)
are associated with a lag of onset that can prolong distress and impairment for patients, and …

D-Serine: potential therapeutic agent and/or biomarker in schizophrenia and depression?

MAB MacKay, M Kravtsenyuk, R Thomas… - Frontiers in …, 2019 - frontiersin.org
D-Serine is a potent co-agonist at the NMDA glutamate receptor and has been the object of
many preclinical studies to ascertain the nature of its metabolism, its regional and cellular …